Today it announced the launch of Skin Brightener, which helps reduce the appearance of freckled and hyperpigmented skin and age spots. Skin Brightener is made from several natural ingredients, including Kojic Acid, Licorice, Chamomile, Aloe, and Evening Primrose Oil.
“This is a unique type of natural skincare product, and we believe that many of our customers will benefit from it,” says Josh Harrison, Director of Pharmacy for New River Naturals.
Skin Brightener is available for purchase online at www.newrivernaturals.com and in spas, weight-loss centers and pharmacies around northeast Tennessee and southwest Virginia.
The addition of Skin Brightener brings the total current number of SKINTRA™ products to seven. New River Naturals is also proud to offer AHA Rejuvenating Cleanser, Gentle Toner, Extra Gentle Hydration Lotion, RejuvaStem Anti-Aging Serum, Intensive Eye Crème, and Glycolic Cellular Turnover Treatment. Learn more at www.newrivernaturals.com.
For media inquiries, contact Robin Roark at (423) 440-3816.
ABOUT NEW RIVER NATURALS
New River Naturals, Inc. (NRN) is a natural health and beauty product company located on the beautiful Valleybrook campus of East Tennessee State University in Kingsport, Tennessee, USA.
NRN is a subsidiary of IPE, Inc., a pharmaceutical technology discovery and development corporation located in Kingsport, Tennessee, USA.
Kingsport, TN (June 12, 2013) – Intellectual Property Executives (IPE) announced today that it is now recruiting participants for the second phase of clinical trials for its new T3 drug to treat hypothyroidism, BCT303. BCT303 successfully completed Phase-1 in August 2012 at Georgetown University Hospital.
BCT303, classified as a 505(b)(2) drug, is a formulation improvement to the active ingredient Liothyronine Sodium, which is already approved by the Food and Drug Administration (FDA). BCT303 utilizes IPE’s patent-pending platform technology for sustained effects and improved stability.
IPE utilized the same platform technology to formulate its T4 drug candidate, BCT304, and its Reverse-T3 drug candidate, BCT305, both of which are ready for IND submission. It has also identified additional 505(b)(2) applications, including treatments for pain-relief and anti-inflammation.
The purpose of this Phase-2 study is to test the efficacy of BCT303, a new thyroid hormone preparation. The thyroid gland produces two thyroid hormones: mostly T4 and a smaller amount of T3. Thyroid hormone therapy for hypothyroidism or thyroid cancer is generally provided using levothyroxine, which is a synthetic form of T4. T4 is converted into the active hormone T3 in the circulation. Therefore, some researchers believe that T3 levels in T4-treated patients may be slightly lower than in individuals whose own thyroid gland is functioning normally. Symptoms of hypothyroidism have been suggested to occur because of this possible T3 deficiency, although this is controversial.
Studies of T3, added to or substituted for T4 in traditional levothyroxine regimens, have generally not shown any benefit of T3. However, it is still possible that no benefit is seen because of the short duration of action or “half-life” of T3. This short-life makes it necessary to dose T3 twice or three times daily. Despite multiple daily doses of T3, T3 levels during its therapy tend to be troubled by peaks and troughs. These peaks can be associated with symptoms of excessive thyroid hormone levels.
This study will look at TSH and thyroid hormone levels following a daily dose of a new preparation of T3 that may have longer duration of action than liothyronine. This preparation of T3 is called Thyromax® or BCT303. The investigators believe that steady levels of T3 will be seen after taking Thyromax®. The investigators believe that in patients with hypothyroidism use of Thyromax® in the correct dose will produce normal TSH levels, without producing symptoms of too much thyroid hormone. The goal of future studies is to test whether Thyromax® may be a potential treatment for hypothyroidism, by comparing it with traditional levothyroxine therapy.
Visit http://ipeamerica.com/bct303-clinical-trials to learn more about the Phase-2 clinical trial.
Intellectual Property Executives (IPE) is a pharmaceutical technology discovery and development corporation located in Kingsport, Tennessee, USA. For more info on IPE’s portfolio of patented technology and pipeline of drug candidates, go to http://www.ipeamerica.com.
We have two new job opportunities available at my company, Intellectual Property Executives (IPE), in Kingsport, TN. To learn more or apply, go to:
IPE’s Drug Development Featured in the Johnson City Press on March 22, 2013:
“Local drug maker hopes to impact major diseases”